# Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics

> **NCT01081769** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 769 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** paliperidone palmitate injection
- **DRUG:** oral antipsychotics

## Key facts

- **NCT ID:** NCT01081769
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 769 (ACTUAL)
- **Last updated:** 2015-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081769, "Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01081769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*